| Non-Small Cell Lung Carcinoma
Braftovi vs Hyrnuo
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Braftovi vs Hyrnuo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsHyrnuo has a higher rate of injection site reactions vs Braftovi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Hyrnuo but not Braftovi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Braftovi
Hyrnuo
At A Glance
Oral
Once daily
BRAF inhibitor
Oral
Twice daily
HER2 kinase inhibitor
Indications
- melanoma
- Colorectal Carcinoma
- Non-Small Cell Lung Carcinoma
- Non-Small Cell Lung Carcinoma
Dosing
melanoma, Non-Small Cell Lung Carcinoma 450 mg (six 75 mg capsules) orally once daily in combination with binimetinib until disease progression or unacceptable toxicity.
Colorectal Carcinoma 300 mg (four 75 mg capsules) orally once daily until disease progression or unacceptable toxicity, in combination with biweekly cetuximab and mFOLFOX6 or FOLFIRI, or weekly cetuximab.
Non-Small Cell Lung Carcinoma 20 mg orally twice daily with food until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=25%) Fatigue, nausea, vomiting, diarrhea, abdominal pain, arthralgia, peripheral neuropathy, decreased appetite, rash, constipation, musculoskeletal pain, hemorrhage, pyrexia.
Serious New primary malignancies, cardiomyopathy, hepatotoxicity, hemorrhage, uveitis, QT prolongation, embryo-fetal toxicity.
Most common (>20%) Diarrhea, rash, paronychia, stomatitis, nausea
Serious Diarrhea, pneumonia, dyspnea, pleural effusion
Pharmacology
Encorafenib is a kinase inhibitor that targets BRAF V600E as well as wild-type BRAF and CRAF, blocking constitutively activated BRAF kinase signaling driven by BRAF V600 mutations that stimulates tumor cell growth; in combination with binimetinib, it targets two kinases in the RAS/RAF/MEK/ERK pathway for greater anti-tumor activity.
Sevabertinib is a reversible kinase inhibitor of HER2 (ERBB2) that also exhibits activity against EGFR; it inhibits HER2 phosphorylation and downstream signaling in cancer cells harboring HER2 alterations and demonstrates antitumor activity in NSCLC models with activating HER2 exon 20 mutations.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Braftovi
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Hyrnuo
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Braftovi
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (0/8)
Hyrnuo
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Braftovi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Hyrnuo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Braftovi Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Hyrnuo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BraftoviView full Braftovi profile
HyrnuoView full Hyrnuo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.